tiprankstipranks
Trending News
More News >

Neuren Pharmaceuticals Announces Quotation of New Securities on ASX

Story Highlights
Neuren Pharmaceuticals Announces Quotation of New Securities on ASX

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).

Neuren Pharmaceuticals Limited announced the quotation of 450,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 30, 2025. This move indicates the company’s ongoing efforts to enhance its financial standing and operational capabilities, potentially impacting its market position and offering new opportunities for stakeholders.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$32.75 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work on treatments that address significant unmet needs in the medical field.

YTD Price Performance: 13.60%

Average Trading Volume: 734,102

Technical Sentiment Signal: Buy

Current Market Cap: A$1.79B

See more data about NEU stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1